drugset / Trial / NCT00785798
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.
Timeline
- Start
- 2009-01
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Vorinostat | Small molecule | 200 mg | — |
| Subject | Vorinostat | Small molecule | 400 mg | — |